DK0460846T3 - Type II interleukin-1-receptorer - Google Patents

Type II interleukin-1-receptorer

Info

Publication number
DK0460846T3
DK0460846T3 DK91304755T DK91304755T DK0460846T3 DK 0460846 T3 DK0460846 T3 DK 0460846T3 DK 91304755 T DK91304755 T DK 91304755T DK 91304755 T DK91304755 T DK 91304755T DK 0460846 T3 DK0460846 T3 DK 0460846T3
Authority
DK
Denmark
Prior art keywords
type
interleukin
receptors
dnas
receptor
Prior art date
Application number
DK91304755T
Other languages
English (en)
Inventor
John Sims
David John Cosman
Stephen D Lupton
Bruce Mosley
Steven K Dower
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK0460846T3 publication Critical patent/DK0460846T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK91304755T 1990-06-05 1991-05-24 Type II interleukin-1-receptorer DK0460846T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53419390A 1990-06-05 1990-06-05
US57357690A 1990-08-24 1990-08-24
US62707190A 1990-12-13 1990-12-13

Publications (1)

Publication Number Publication Date
DK0460846T3 true DK0460846T3 (da) 2002-06-10

Family

ID=27415141

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91304755T DK0460846T3 (da) 1990-06-05 1991-05-24 Type II interleukin-1-receptorer

Country Status (12)

Country Link
US (1) US20030060616A1 (da)
EP (1) EP0460846B1 (da)
JP (2) JP3155024B2 (da)
AT (1) ATE213743T1 (da)
AU (1) AU651596B2 (da)
DE (1) DE69132937T2 (da)
DK (1) DK0460846T3 (da)
ES (1) ES2172502T3 (da)
IE (1) IE911771A1 (da)
IL (1) IL98205A (da)
NZ (1) NZ238255A (da)
WO (1) WO1991018982A1 (da)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US5470730A (en) * 1990-09-28 1995-11-28 Immunex Method for producing TH -independent cytotoxic T lymphocytes
DE69131577T2 (de) * 1990-09-28 2000-05-04 Immunex Corp Verfahren zur herstellung th-unabhängiger zytotoxischer t-zymphozyten
WO1993019777A1 (en) * 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5538863A (en) * 1993-07-01 1996-07-23 Immunex Corporation Expression system comprising mutant yeast strain and expression vector encoding synthetic signal peptide
AU729873B2 (en) * 1993-12-14 2001-02-15 University Of Pittsburgh Systemic gene treatment of connective tissue diseases
US6274708B1 (en) 1994-09-05 2001-08-14 Amrad Operations Pty Ltd. Mouse interleukin-11 receptor
AU690743B2 (en) * 1994-09-05 1998-04-30 Walter And Eliza Hall Institute Of Medical Research, The A novel haemopoietin receptor
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
NZ510497A (en) 1998-08-21 2003-09-26 Immunex Corp Human IL-1 epsilon DNA and polypeptides
EP1939297A1 (en) 1998-09-24 2008-07-02 Pharmacia & Upjohn Company LLC Alzheimer's disease secretase
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6693172B1 (en) 1999-05-27 2004-02-17 Pharmacia And Upjohn Company Double mutant alpha-7 nicotinic acetylcholine receptor
US6455290B1 (en) 1999-07-09 2002-09-24 Pharmacia Italia S.P.A. Tankyrase homolog protein (THP), nucleic acids, and methods related to the same
JP2003512838A (ja) 1999-10-22 2003-04-08 ファルマシア・アンド・アップジョン・カンパニー ショウジョウバエｇタンパク質結合レセプター、核酸、およびそれに関連する方法。
ES2433011T3 (es) 1999-12-20 2013-12-05 Immunex Corporation Receptor TWEAK
US6498026B2 (en) 2000-02-25 2002-12-24 Hercules Incorporated Variant galactose oxidase, nucleic acid encoding same, and methods of using same
EP1297112A2 (en) 2000-05-22 2003-04-02 PHARMACIA & UPJOHN COMPANY Novel matrix metalloproteinases
US7259244B2 (en) 2000-06-16 2007-08-21 Nerviano Medical Sciences S.R.L. Human homologue of the DBF4/ASK1 protein, nucleic acids, and methods related to the same
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
AU2001271839A1 (en) 2000-07-05 2002-01-14 Pharmacia And Upjohn Company Human ion channels
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
AU2002324625B2 (en) * 2001-08-07 2008-05-08 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
CA2462790A1 (en) 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4
PL376821A1 (pl) 2002-03-27 2006-01-09 Immunex Corporation Sposoby zwiększania produkcji polipeptydów
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
MXPA06000974A (es) 2003-07-25 2006-08-31 Amgen Inc Antagonistas y agonistas de ldcam y metodos para su uso.
EP1730174B1 (en) 2004-03-05 2010-04-21 The Board Of Trustees Of The University Of Illinois Peptide carrier for drug delivery
US7319015B2 (en) 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
US7582442B2 (en) 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
WO2005116069A2 (en) 2004-04-14 2005-12-08 Monell Chemical Senses Center Taste receptors of the t1r family from domestic dog
ES2570665T3 (es) 2004-04-23 2016-05-19 Zoetis Services Llc Factor de permisividad celular para virus, y usos del mismo
JP4722048B2 (ja) * 2004-07-27 2011-07-13 独立行政法人理化学研究所 Ｎ−デアセチラーゼ／ｎ−スルホトランスフェラーゼ２を発現するベクター
KR20070009269A (ko) 2005-07-15 2007-01-18 한국생명공학연구원 재조합단백질 생산용 단백질융합인자 라이브러리 및이로부터 획득된 단백질융합인자
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
EP2500415A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
BRPI0815368A2 (pt) 2007-08-21 2015-02-10 Amgen Inc "proteinas c-fms humanas a antigeno"
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
JP2009183176A (ja) * 2008-02-05 2009-08-20 Univ Of Tokyo Ｉｌ−１タイプｉｉレセプター遺伝子の欠損変異体マウス
GB0803076D0 (en) 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
US8052970B2 (en) 2008-06-30 2011-11-08 The Regents Of The University Of Michigan Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
EP2328908A4 (en) 2008-08-28 2012-11-28 Univ New York State Res Found TREATMENT OF AMYLOIDOSES BASED ON MYELIN BASED PROTEIN AND FRAGMENTS THEREOF
EP2370470B1 (en) 2008-12-04 2016-10-05 Korea Research Institute of Bioscience and Biotechnology Screening of abundantly secreted proteins and their use as fusion partners for the production of recombinant proteins
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US8293100B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
US20120076754A1 (en) 2009-05-20 2012-03-29 Ziad Mallat Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20120311728A1 (en) 2009-11-06 2012-12-06 Ziad Mallat Methods and pharmaceutical composition for the treatment of atherosclerosis
US8759293B2 (en) 2009-11-13 2014-06-24 Grifols Therapeutics Inc. von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
ES2477498T3 (es) 2010-01-20 2014-07-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Proteína 4 del tipo angiopoyetina (ANGPTL4) para el mantenimiento de la integridad de la barrera celular del endotelio vascular
EP2556086B1 (en) 2010-04-09 2015-03-04 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
SG187198A1 (en) 2010-08-05 2013-03-28 Amgen Inc Dipeptides to enhance yield and viability from cell cultures
EP2621511A1 (en) 2010-09-28 2013-08-07 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of bone density related diseases
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
ES2668895T3 (es) 2011-03-16 2018-05-23 Amgen Inc. Variantes de Fc
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
ES2560012T3 (es) 2011-05-10 2016-02-17 Institut National De La Santé Et De La Recherche Médicale (Inserm) Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
CN107988166B (zh) 2011-07-01 2022-03-15 美国安进公司 哺乳动物细胞培养
WO2013009971A1 (en) 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Detection and screening method and materials useful in performance thereof
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EA201490555A1 (ru) 2011-09-02 2014-07-30 Эмджен Инк. Фармацевтический продукт и способ анализа реакции фармацевтического продукта на свет
KR102007055B1 (ko) 2011-09-22 2019-08-02 암젠 인크 Cd27l 항원 결합 단백질
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
ES2638649T3 (es) 2011-11-28 2017-10-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Composición farmacéutica para su uso en el tratamiento de disfunciones asociadas al envejecimiento
TW201329104A (zh) 2011-12-08 2013-07-16 Amgen Inc 人類ｌｃａｔ抗原結合蛋白質及其治療用途
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
HUE053362T2 (hu) 2012-04-27 2021-06-28 Novo Nordisk As Emberi CD30-ligand antigént kötõ fehérjék
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
CN104519898A (zh) 2012-06-06 2015-04-15 国家健康与医学研究院 用于治疗癌症的方法和药物组合物
AU2013292510A1 (en) 2012-07-19 2015-02-05 Amgen Inc. Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9783789B2 (en) 2012-12-07 2017-10-10 North Carolina State University Beta-hexosyl-transferases and uses thereof
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
AU2014244444A1 (en) 2013-03-14 2015-09-24 Amgen Inc. CHRDL-1 antigen binding proteins and methods of treatment
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
EP4026596A1 (en) 2013-03-14 2022-07-13 Amgen, Inc Removal of leaked affinity purification ligand
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
EP2970483A2 (en) 2013-03-15 2016-01-20 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2014144632A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Human pac1 antibodies
WO2014144553A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
PL3456743T3 (pl) 2013-05-30 2022-03-07 Kiniksa Pharmaceuticals, Ltd. Białka wiążące antygen receptora onkostatyny m
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
JP6668241B2 (ja) 2013-09-05 2020-03-18 アムジエン・インコーポレーテツド 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子
WO2015048272A1 (en) 2013-09-25 2015-04-02 Amgen Inc. V-c-fc-v-c antibody
US11130980B2 (en) 2013-10-31 2021-09-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
WO2015086727A2 (en) 2013-12-11 2015-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method for patients suffering of a cancer
KR102381791B1 (ko) 2014-01-13 2022-03-31 암젠 인크 재조합 단백질의 고수준 만노스 글리코폼 함량을 조작하기 위한 오르니틴 대사의 조절
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
SG10201912081RA (en) 2014-01-29 2020-02-27 Amgen Inc Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
AU2015218903B2 (en) 2014-02-20 2020-10-15 Allergan, Inc. Complement component C5 antibodies
KR20160126054A (ko) 2014-02-27 2016-11-01 알러간, 인코포레이티드 보체 인자 Bb 항체
SG11201610143VA (en) 2014-06-04 2017-01-27 Amgen Inc Methods for harvesting mammalian cell cultures
EP3194435A1 (en) 2014-09-15 2017-07-26 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
MX2017006463A (es) 2014-11-19 2018-04-20 Amgen Inc Cuantificacion de porcion de glicano en glicoproteinas recombinantes.
WO2016089919A1 (en) 2014-12-01 2016-06-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
UA126270C2 (uk) 2015-04-10 2022-09-14 Емджен Інк. Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
JP6932700B2 (ja) 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用
EP3699269A1 (en) 2015-09-22 2020-08-26 F. Hoffmann-La Roche AG Expression of fc-containing proteins
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
EP3390447A1 (en) 2015-12-15 2018-10-24 Amgen Inc. Pacap antibodies and uses thereof
WO2017112824A2 (en) 2015-12-23 2017-06-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
KR20180133198A (ko) 2016-05-04 2018-12-13 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
IL285146B (en) 2016-07-22 2022-09-01 Amgen Inc Methods for purifying proteins involving fc
CA3043528A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
CA3049110A1 (en) 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
EP3642239A1 (en) 2017-06-20 2020-04-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
US20210346513A1 (en) 2017-08-04 2021-11-11 Amgen Inc. Method of conjugation of cys-mabs
KR20200110362A (ko) 2018-01-12 2020-09-23 암젠 인크 Pac1 항체 및 이의 용도
US20210379146A1 (en) 2018-10-04 2021-12-09 Inserm (Institut National De La Santé Et De La Recherche Médigale) Method to restore or improve cognitive functions
SG11202106049RA (en) 2018-12-10 2021-07-29 Amgen Inc Mutated piggybac transposase
KR20220016139A (ko) 2019-05-30 2022-02-08 암젠 인크 항체 이량체화를 유도하기 위한 경첩 영역 조작
MX2021015791A (es) 2019-06-28 2022-04-01 Amgen Inc Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1.
MX2022001866A (es) 2019-08-13 2022-03-11 Amgen Inc Muteinas de interleucina-2 para la expansion de celulas t reguladoras.
EP4054590A1 (en) 2019-11-04 2022-09-14 Amgen Inc. Methods for treating leukemia
MX2022005566A (es) 2019-11-08 2022-07-19 Amgen Inc Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.
EP4061838A1 (en) 2019-11-19 2022-09-28 Amgen Inc. Novel multispecific antibody format
CA3162705A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
CA3164129A1 (en) 2019-12-20 2021-06-24 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
CA3191710A1 (en) 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
WO2022076474A2 (en) 2020-10-07 2022-04-14 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
TW202233660A (zh) 2020-10-30 2022-09-01 美商安進公司 過表現胰島素樣生長因子受體突變體以調節ｉｇｆ補充
WO2022103773A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Novel linkers of multispecific antigen binding domains
CA3216559A1 (en) 2021-04-20 2022-10-27 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
EP4330281A1 (en) 2021-04-29 2024-03-06 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
WO2022261299A1 (en) 2021-06-10 2022-12-15 Amgen Inc. Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3
TW202328442A (zh) 2021-09-10 2023-07-16 美商安進公司 平臺宿主對ｉｇｆ—培養基之適應
WO2023129974A1 (en) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Generation of landing pad cell lines
WO2023172965A1 (en) 2022-03-09 2023-09-14 Amgen Inc. Optimized transfection protocol
WO2023175022A1 (en) 2022-03-16 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat infectious diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5198542A (en) * 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
WO1991000742A1 (en) * 1989-07-07 1991-01-24 E.I. Du Pont De Nemours And Company Soluble human b-cell interleukin-1 receptor

Also Published As

Publication number Publication date
NZ238255A (en) 1992-03-26
ATE213743T1 (de) 2002-03-15
ES2172502T3 (es) 2002-10-01
EP0460846B1 (en) 2002-02-27
EP0460846A1 (en) 1991-12-11
WO1991018982A1 (en) 1991-12-12
JPH0767651A (ja) 1995-03-14
US20030060616A1 (en) 2003-03-27
JP2000336039A (ja) 2000-12-05
DE69132937D1 (de) 2002-04-04
AU651596B2 (en) 1994-07-28
IL98205A0 (en) 1992-06-21
IL98205A (en) 1998-01-04
DE69132937T2 (de) 2002-09-19
AU7908191A (en) 1991-12-31
JP3155024B2 (ja) 2001-04-09
JP3652582B2 (ja) 2005-05-25
IE911771A1 (en) 1991-12-18

Similar Documents

Publication Publication Date Title
DE69132937D1 (de) Typ-II-Interleukin-1-Rezeptoren
LU90591I2 (fr) Enbrel-etanercept
ES2103706T3 (es) Receptores de interleuquina-4.
ATE169956T1 (de) Dna, die für proteine kodiert, die menschliches il-1 binden
DE69016508D1 (de) Interleukin-7-Rezeptoren.
DE69632658D1 (de) Expression in der selben Zelle von Polypeptide vom schweinen reproduktiven und respiratorischen Syndrom
ATE233788T1 (de) Interleukin-15-rezeptoren
DE3851035D1 (de) Interleukin-7.
ATE282691T1 (de) Chemokin typ cc-ahnliches protein
CO4340654A1 (es) Procedimientos para producir proteina c
DK0494260T3 (da) Receptorer for granulocytkolonistimulerende faktor